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ENGLISH SUMMARY 
Neurodegenerative diseases are becoming more prevalent due to the increased 
lifespan of the general population as aging is the primary risk factor for the majority 
of neurodegenerative diseases. The symptoms vary depending on the given 
neurodegenerative disease, ranging from cognitive decline, learning and memory 
deficits, hallucinations to motor defects. Unfortunately, there is no cure for any of the 
devastating neurodegenerative diseases, and most treatment options are symptomatic 
and do therefore not address the underlying cause of pathology. Furthermore, although 
many drug candidates have been developed, it has proven more complicated than 
anticipated to deliver therapeutics to the brain due to restraints of the brains 
vasculature. The blood-brain barrier (BBB) is composed of highly specialized brain 
capillary endothelial cells (BCECs) that are characterized by tight interconnections 
and low passive permeability. The BBB separates the brain parenchyma from the 
blood, ensuring that harmful molecules in the bloodstream do not reach the brain, 
however, it also keeps most macromolecules and therapeutics out of the brain 
parenchyma as well.  
The BCECs express various receptors and transporters on the cell membrane, which 
allows for active transport of molecules essential for the brain e.g. amino acids, 
glucose, vitamins, and essential metals.  These receptors and transporters can also be 
utilized to deliver therapeutics across the barrier via specific targeting of molecular 
constructs. Hence, by conjugating drugs or drug-encapsulated nanoparticles to 
molecules that specifically interacts with a receptor or transporter selectively 
expressed on the luminal side of BCECs, uptake and transport of such constructs 
across the BBB can be increased substantially compared to injection of non-targeted 
drugs.  
The expression of nutrient receptors and transporters suitable as drug delivery targets 
may, however, be altered due to inflammation and other pathological factors 
associated with neurodegenerative diseases. However, the alteration in expression 
levels at the BBB are poorly understood. Possible alterations of these targets may 
occur not only at the transcriptional level, but also by epigenetic modifications. 
In this dissertation, the expression of three suitable targets for drug delivery, Cluster 
of Differentiation 98 Heavy Chain (CD98hc), glucose transporter 1 (Glut1), and 
transferrin receptor 1 (TfR1), were investigated in models of brain pathology. 
Furthermore, the possibility of regulating their expression using epigenetic inducer, 
valproic acid, was explored. 
It was found that it was indeed possible to epigenetically upregulate BCECs 
expression of receptors and transporters, however the increased expression did not 
increase the transport across the barrier of targeted drug-carriers.  
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Neuroinflammation is a common feature in neurodegenerative diseases. However, 
little research has been carried out investigating the transcriptional alterations of these 
targets during neuroinflammation. The expression of CD98hc, Glut1, and TfR1 by the 
BCECs during neuroinflammation was further investigated in experimental 
lipopolysaccharide (LPS) models both in vivo and in vitro. The latter was employed 
in order to optimize the identification of early molecular alterations during 
neuroinflammation by constructing a new in vitro BBB model using BCECs and 
mixed glial cells that displayed prominent secretion of proinflammatory cytokines 
without completely demolishing the integrity of the barrier.  Collectively, the data 
from acute and persistent inflammation induced by LPS did not influence the 
expression of CD98hc, Glut1 and TfR1 in BCECs, which was contrasted by marked 
increases in expression of ICAM-1 and VCAM-1.   
In conclusion, the results presented in this dissertation provide new insight into the 
prospective of using epigenetic agents for enhancement of the expression of drug 
delivery targets on the BCECs. The dissertation also highlights the importance of 
considering transcriptional alterations in expression of surface receptors and nutrient 
transporters on BCECs in response to neuroinflammation, a common feature of 
neurodegenerative diseases, which could influence the transport of targeted 
therapeutics.  





Da aldring er den største risikofaktor for udvikling af neurodegenerative sygdomme, 
bliver disse sygdomme mere udbredte hos hele befolkningen i takt med at den 
gennemsnitlige levealder stiger. Symptomerne varierer afhængigt af, hvilken 
neurodegenerativ sygdom patienten rammes af, men inkluderer ofte kognitive 
vanskeligheder, indlæringsbesvær, hukommelsestab, hallucinationer og motoriske 
defekter. Der findes desværre ingen helbredende behandling, og de fleste 
behandlingsmuligheder er symptomatiske og afhjælper derfor ikke den underliggende 
patologiske årsag. Selvom der udvikles mange lægemiddelkandidater, har det vist sig 
at være mere kompliceret end forventet at levere behandling effektivt til hjernen. 
Årsagen er blod-hjernebarrieren, som består af højt specialiserede endotelceller, som 
karakteriseres ved meget tætte intercellulære forankringer og lav passiv permeabilitet. 
Blod-hjernebarrieren adskiller hjernen fra blodet for at sikre, at skadelige molekyler 
som cirkulærer i blodbanen ikke når frem til hjernevævet, men samtidigt holder den 
også de fleste makromolekyler og lægemidler ude.  
Grundet den begrænsede passive permeabilitet igennem blod-hjernebarrieren skal de 
fleste næringsstoffer aktivt transporteres ved hjælp af specifikke transportmolekyler. 
Transportmolekylerne eller targets, som inkluderer receptorer og transporters, kan 
også anvendes til at levere lægemidler over barrieren ved at målrette lægemidlet mod 
disse targets. Ved at konjugere lægemidler eller indkapslede nanopartikler til 
molekyler, som specifikt interagerer med en receptor, der selektivt udtrykkes på den 
luminale side af endotelcellen, kan optagelse og transport over BBB forøges.  
Ekspressionen af disse targets kan ændres ved inflammation, eller andre patologiske 
faktorer forbundet med neurodegenerative forandringer, som kunne ændre 
ekspressionen i blod-hjernebarrieren, men det fænomen er endnu ikke fuldt klarlagt. 
Transkriptionelle ændringer kan bl.a. skyldes epigenetiske modifikationer. 
I denne afhandling er ekspressionen af tre targets, CD98hc, Glut1 og TfR1, ved blod-
hjernebarrieren blevet undersøgt i patologiske modeller. Det er ligeledes undersøgt 
om det er muligt at regulere ekspressionen af CD98hc, Glut1 og TfR1 på baggrund af 
epigenetiske mekanismer. Ved hjælp af histon-deacetylase hæmmeren valporate var 
det muligt at øge blod-hjernebarrierens ekspression af targets, men denne 
opregulering i endotelcellerne var ikke ensbetydende med højere transport over 
barrieren. 
Neurodegenerative sygdomme ledsages ofte af en tilstand med neuroinflammation, 
men der er udført meget lidt forskning, der undersøger de transkriptionelle ændringer 
af de førnævnte targets ved neuroinflammation. Neuroinflammation blev derfor 
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induceret ved hjælp af lipopolysaccharid både in vivo og in vitro for at undersøge om 
ekspressionen af CD98c, Glut1 eller TfR ændres under neuroinflammatoriske forhold. 
For bedre at kunne identificere tidlige molekylære ændringer blev der etableret en 
alternativ inflammatorisk in vitro blod-hjernebarriere model, som viste høj sekretion 
af inflammatoriske cytokiner uden ledsagende ødelæggelse af barriereintegriteten. 
Data fra akut og vedvarende inflammation induceret af LPS, viser stabil ekspression 
af CD98hc, Glut1 og TfR1 i endotelcellerne, men markante stigninger i ekspressionen 
af ICAM-1 og VCAM.  
Resultaterne præsenteret i denne afhandling giver ny indsigt i potentialet af 
epigenetiske modulatorer til at øge ekspressionen af targets på blod-hjernebarrierens 
endotelceller. Afhandlingen fremhæver ligeledes vigtigheden af de transkriptionelle 
ændringer på blod-hjernebarrierens endotelceller som konsekvens af neuro-
degenerative sygdomme ledsaget af en neuroinflammatorisk tilstand, hvilket 
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CHAPTER 1. INTRODUCTION  
Neurodegenerative diseases of the central nervous system (CNS) are becoming 
increasingly common due to the prolonged lifespan of the general population (1). 
Even though many different neurodegenerative diseases exist, some common 
characteristics are progressive cellular dysfunction of neurons in the brain or spinal 
cord, involving cell death in specific areas of the CNS (2). Neurodegenerative diseases 
include Alzheimer´s disease (AD), Parkinson´s disease (PD) and Multiple Sclerosis 
(MS). Currently, there is no cure for any of the aforementioned diseases, and the 
diagnosis is devastating to patients and their families. With the increasing prevalence 
of neurodegenerative diseases, it is vital to develop better treatment options. Many 
novel drug candidates have been created in hopes of treating neurodegenerative 
diseases, but none have evolved to be among the current treatment options. 
Unfortunately, it is much more complicated to treat brain diseases than disorders 
elsewhere in the body due to the blood-brain barrier (BBB). As a result, delivering 
therapeutics to the bloodstream and hoping that the drug will reach the brain is 
extremely inefficient (3). The BBB keeps harmful agents from entering the brain 
parenchyma (4), but at the same time it hinders the transport of therapeutics through 
the BBB in sufficient amounts to elicit a pharmacological response (5). Several 
strategies have been explored in order to deliver macromolecules across the BBB. 
Despite the effort, a highly specific and efficient drug delivery strategy has not been 
developed. One of the biggest hurdles is unspecific targeting, which results in poor 
accumulation of a drug within the CNS, which is then not efficacious in slowing 
cognitive decline (6). 
Targeting of the BBB can be obtained by adding specific ligands on the surface of a 
drug that will then bind to a receptor or nutrient transporter that is highly or selectively 
expressed on the brain endothelium. However, limited information and understanding 
of how the expression of BBB specific transporters alters during neurodegeneration 
remains a challenge (7). Furthermore, most studies that investigate drug delivery 
through the BBB are conducted on a healthy and intact BBB, neglecting the matter of 
aging and inflammation associated with neurodegenerative diseases (8). 
Inflammation, whether it originates from the periphery or from the CNS itself, can 
affect the expression of transporters located on the brain capillary endothelial cells 
(BCECs) (9) and the same can be said about aging (10). These transcriptional 
alterations of receptors and nutrient transporters due to various environmental 
influences are not well understood, but there are some indications that they might be 
due to epigenetic modifications. However, possible epigenetic regulation of 
transporters on the BCECs surface in response to neurodegenerative pathology has 
not been comprehensively investigated.  
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The expression and availability of surface targets on the BCECs in a healthy and 
pathological BBB will therefore be discussed in the current thesis where the aim of 
the PhD project are to:  
 Investigate specific targets of the BBB with focus on transcriptional and 
translational expressional changes in vitro and in vivo following 
experimental inflammation. 
 Investigate whether it is possible to upregulate expression of drug delivery 




CHAPTER 1. INTRODUCTION 
19 
1.1. THE BLOOD-BRAIN BARRIER 
The brain requires a highly balanced and stable microenvironment to ensure normal 
function of neurons and their finely tuned electrical and chemical signaling (11). The 
main protective strategy against influx of toxins, pathogens, and other harmful 
molecules to the brain is denoted by the vascular barrier system, consisting of the BBB 
and the blood-cerebrospinal fluid barrier (4,12,13). The BBB will be the main focus 
of the thesis and the blood-cerebrospinal fluid barrier will therefore not be discussed 
further. The BBB itself consists of BCECs that form tight junctions between each 
other (14). Pericytes surround the BCECs, and are embedded in the basement 
membrane (BM)(14). The last cellular layer that helps regulate the function of the 
BBB is astrocytes, which cover the BM almost completely by their endfeet (14,15). 
In order to develop new ways of delivering therapeutics to the brain, the structure and 
function of the BBB must be understood in detail. The following sections will cover 
the structure and function of the BBB focusing on the cells associated with BBB 
integrity.  
 
Figure 1: Schematic illustration of the cellular content that supports the blood-
brain barrier (BBB). The endothelial cells (E) make up the BBB that is supported by 
pericytes (P) and astrocytes (A). The basement membrane (BM) surrounds the 
pericytes. Illustration is a modified version from Maj Schneider Thomsen (16).  
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BRAIN CAPILLARY ENDOTHELIAL CELLS  
The brains microvasculature is comprised of a monolayer of non-fenestrated and 
highly specialized BCECs, which are closely associated with pericytes and astrocytes 
that support and maintain the barrier integrity (13,14). The luminal surface of BCECs 
is covered by glycocalyx, which are glycoproteins that can prevent some interactions 
between BCECs and larger molecules (17). The abluminal surface of the BCECs is 
covered by the BM, which is only 20 nm thick and made up of structural proteins such 
as laminins, collagens and proteoglycans (15,17).  
A key feature of the BCECs is the combination of physical- and molecular barrier 
properties (18). The physical barrier is due to tight junction (TJ) protein complexes, 
which are the basis for low paracellular transport and transcytosis (18–20). These 
protein complexes are occludin and claudin-1, -3, -5, -12, where claudin-5 is the most 
abundant (19). They are then connected to cytoplasmic scaffold proteins zonula 
occludens 1-3 (ZO1-3) and cingulins, which bind to the actin cytoskeleton. Junctional 
adhesion molecules are transmembrane proteins that interact with TJ and participate 
in restricting paracellular transport (21). Various adherent junctional proteins, such as 
vascular endothelial-cadherin, vaceolin-1 and platelet endothelial cell adhesion 
molecule-1, also help regulate the BBB integrity (3,22).  
Due to the low permeability of the barrier as well as low levels of transcytosis, most 
nutrients need to be actively transported. Various transporters are therefore expressed 
on the BCECs to ensure sufficient supply of hydrophilic nutrients and metabolites 
(23). This is a very energy demanding task and the BCECs do therefore contain more 
mitochondria than any other endothelial cells (18). The high amount of mitochondria 
is crucial for generating sufficient adenosine triphosphate to drive the ion gradient that 
is critical for transport of molecules from blood to brain, or waste products from brain 
to blood (18). BCECs express two distinct types of transporters: efflux transporters, 
and nutrient transporters (18). Some substances enter the BBB by passive diffusion 
such as lipophilic molecules, oxygen (O2), carbon dioxide (CO2), as well as some 
hydrophilic molecules smaller than 400 Da that contain fewer than nine hydrogen 
bonds. Even so, not all small lipophilic molecules diffuse through the BCECs (3,24). 
This is due to the expression of efflux transporters, such as multidrug resistance 
protein and P-glycoprotein that can transport the molecules up their concentration 
gradients back to the bloodstream (14,25). These efflux transporters are usually 
located at the luminal surface of the BCECS and make up the molecular barrier section 
of the BBB (18).  
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PERICYTES  
The cells in closest proximity to BCECs are pericytes, which are multi-functional, 
polymorphic mural cells that are present along the walls of capillaries, along arterioles 
and post-capillary venules (26). Pericytes are crucial for development of the BBB 
(27,28) and continue to be of importance throughout the lifespan (27,29,30). They 
support BBB function, stabilize newly formed capillaries, regulate immune cell entry 
to the brain, aid in scar formation, and may even regulate cerebral blood flow 
(26,31,32). Pericytes are also able to determine the number of BCECs tight junctions 
and control the polarization of astrocytic end-feet (29,33). Pericytes are separated 
from the BCECs by the BM (18,30,34–36) but extend long cellular processes to the 
BCECs and they are therefore directly linked through so-called peg-and-socket 
interactions, which is crucial for BBB integrity (37,38). Pericytes and endothelial cell 
cross talk is not well understood. However, it is known that platelet-derived growth 
factor beta (PDGF-β) is secreted by BCECs, which binds to platelet-derived growth 
factor receptor beta (PDGFRβ) on pericytes and initiates various signal transduction 
pathways that regulate pericytes recruitment and proliferation (30,39). PDGFRβ has 
recently been suggested to protect the BBB in mice following a stroke (40). 
Additionally, pericytes seem to control the cell cycle of BCECs and contribute to the 
formation of the BM (41).  
Pericyte coverage seems to be greatly associated with the permeability of the BBB as 
well as neurodegeneration, where the permeability becomes compromised in different 
brain regions (42,43). Even though the BBB gets referred to as a whole, various 
studies have shown that permeability for certain molecules varies between brain 
regions that cannot be explained by increased expression of receptors (42,44,45). Due 
to aging, the initial decrease in BBB integrity occurs in the hippocampus, which has 
been correlated with pericyte injury in the area (42,46). How reduced coverage or 
injury to pericytes affects the permeability of the BCECs seems to be related to 
increased transcytosis as pericyte deficient mice displayed increased water content, 
albumin, immunoglobulin G (IgG), 70 kDa dextran and uptake of macrovesicles in 
the brain, without degradation of tight junction complexes (29). Interestingly, the 
BCECs were, in some areas of the brain such as the midbrain, able to maintain low 
transcytosis despite decreased pericyte coverage (42). One possible explanation is the 
heterogeneity of pericytes and their localization in the brain (42). Pericytes in the 
forebrain originate from the neuroectoderm whereas pericyte located in the midbrain 
originate from the mesoderm (42), so their function may differ. Another possibility is 
that pericyte coverage is not the sole regulator of BBB permeability (42).  
Due to the aforementioned heterogeneity in terms of origin and function of pericytes, 
they express different cellular markers (47). Some pericytes share expression of 
markers with smooth muscle cells, which are present in the wall of arteries and 
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arterioles (33). These entail contractile proteins such as alpha-smooth muscle actin (α-
SMA), tropomyosin and myosin (31,48). In order to identify pericytes, commonly 
used markers include α-SMA, PDGFRβ and CD13 (33,47). These are expressed at 
various differential state of the pericytes, as well as in response to stimulation (49) 
and can therefore provide information on the location and function of the pericyte. 
ASTROCYTES  
The next cellular layer that supports the BCECs is the astrocytes. Astrocytes are 
heterogenic, star-shaped and multifunctional cells that are considered to be the most 
abundant glia cell type (18). Astrocytic endfeet cover the BM almost completely 
(14,15) and can control CNS blood flow by releasing molecular mediators such as 
prostaglandins, nitric oxide, and arachidonic acid (50,51). Besides covering the BM, 
astrocytes are also functionally connected to each other and oligodendrocytes through 
gap junctions (52,53). In addition, they extend their processes to neurons and can 
thereby regulate the neuronal activity and participate in synaptic cleft clearing of 
neurotransmitters (50,54). This close connection is essential for astrocytic supply of 
antioxidants, growth factors and other essential nutrients to the neurons. (55,56).  
Another important function of astrocytes, that protects the metabolically sensitive 
neurons, is supplying energy. Astrocytes take up glucose, transform it to lactate or 
store it as glycogen (57). Astrocytes are the main storage site of glycogen granules in 
the brain, which they can transform to lactate and secrete to neurons during 
hypoglycemia or high neuronal activity (58). When glucose storage is low, astrocytes 
are also able to induce expression of glucose transporter 1 (GLUT1) on BCECs (59), 
which increases transport of glucose through the BBB.  
Astrocytes are important immune regulators within the brain as they are able to secrete 
various inflammatory mediators when activated. They can become activated by 
oxidative stress, pro-inflammatory cytokine release from adjacent cells, damage-
associated molecular patterns, pathogen associated patterns, or endotoxins (50,60,61). 
Reactive astrogliosis is the response of astrocytes that is seen in many 
neurodegenerative diseases (62). It entails changes in transcriptional regulation, 
morphological and physiological alteration resulting in gain of new functions or loss 
of homeostatic ones (63). It is a defense mechanism aiming to limit tissue damage and 
restoring CNS homeostasis mainly in response to BBB disruption (63). However, 
chronic astrogliosis leads to inhibition of neural plasticity (62). Astrocytes can exert 
either pro- or anti-inflammatory functions, dependent on stimuli (64). Pro-
inflammatory astrocytes will release pro-inflammatory interleukins (IL) e.g. IL-1β, 
IL-6 as well as tumor necrosis factor alpha (TNF-α), whereas an anti-inflammatory 
astrocyte will release e.g. IL-10 and transforming growth factor beta (TGF-β) (65,66). 
Nonetheless, the phenotype of reactive astrocyte and thereby the secreted cytokines 
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can vary depending on the type of insult or inflammatory stimuli (67).  
Astrocytes can be identified by their structure and expression of certain markers (68). 
Expression of glia fibrillary acid protein (GFAP) has been a popular astrocyte marker 
for many years. Astrocytes increase their expression of GFAP when reactive, but 
GFAP is also expressed in non-reactive astrocytes in vivo (56). GFAP content of 
astrocytes varies between brain regions, where cortical, thalamic or striatal astrocytes 
express more GFAP without being more reactive than astrocytes elsewhere in the 
brain (63). GFAP has been extensively investigated, and expression of GFAP is not 
essential for appearance and function of astrocytes in an healthy brain (69), but it is 
crucial for reactive astrogliosis and scar formation (70). Other popular molecular 
markers used to identify astrocytes are glutamine synthetase and S100β (56,71). 
The complicated nature of the ever-changing BBB is reflected in the complex 
interaction between its cellular components. Even though the BBB refers to the tightly 
connected BCECs, the regulation of the BBB is highly dependent on pericytes and 
astrocytes as the integrity of the barrier is regulated by coverage and secretion of 
various molecular mediators.  
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1.2. TRANSPORT AT THE BLOOD-BRAIN BARRIER 
Due to the BBB, numerous molecules must be actively transported to the brain in 
order to deliver the crucial nutrition and ions. Transport through BBB can be classified 
into five main categories: passive diffusion, paracellular diffusion, carrier mediated 
transport, receptor mediated transcytosis, and adsorptive mediated transport (see 
Figure 2) (14,22). Each of the aforementioned will be briefly mentioned in the 
following section, but the focus will be on carrier mediated transport and receptor 
mediated transport as these are of great interest for drug delivery. Furthermore, a few 
receptors that are of importance for the current thesis will be discussed in details.  
Transcellular passage of non-polar, small (<400 Da) lipophilic molecules or gasses 
such as O2 or CO2 can be achieved by passive diffusion across the BCECs following 
their concentration gradient (see Figure 2). (3,24). Furthermore, a few small polar, 
hydrophilic molecules such as water, alcohol, nicotine, and morphine can pass the 
BCECs by paracellular diffusion through the TJs (13,14,72) (see Figure 2).  
Adsorptive mediated transcytosis is utilized by molecules that are positively charged 
and can interact with binding sites on the negatively charged cell surface of the BCECs 
(73,74). That binding will induce endocytosis and subsequent transcytosis (72,75). 
This route does not depend on specific matching receptors and ligands like receptor-
mediated transport. Molecules transported via this route are cationised albumin, 
avidin, and various cell-penetrating peptides (14).  
 
Figure 2: Transport mechanisms at the blood-brain barrier. The paracellular route 
can be taken by small hydrophilic molecules, whereas small lipophilic molecules 
utilize the transcellular route. Carrier mediated transport (CMT) is dependent on 
solute carrier proteins and is the route glucose and amino acids take. Receptor 
mediated transport (RMT) requires a specific receptor on the luminal side of the brain 
capillary endothelial cell to be present. Adsorptive mediated transport is obtainable 
for positively charged molecules. Figure is from Barar et al. (76) 
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CARRIER MEDIATED TRANSPORT  
Specific transport systems supply the brain with adequate nutrition which is regulated 
by the metabolic needs of the brain (22). Small molecules, such as glucose (77), amino 
acids (78), vitamins (79), and hormones (80) utilize carrier-mediated transport (CMT), 
that requires a solute carrier protein to be present (see Figure 2). Essential amino acids 
are transported through the L-type amino acid transporter 1 (LAT1) or LAT2, and 
cationic amino acids are transported through the cationic amino acid transporter 1 and 
3 (81). Another example of an important transporter is the Major facilitator 
superfamily domain-containing protein 2a that is a lysophosphatidylcholine bound 
fatty acids transporter for fatty acids such as omega-3 fatty acid docosahexaenoic acid 
(82,83) which is expressed selectively and exclusively by the BCECs. Even 
nucleotides and bases necessary for DNA and RNA synthesis are transported through 
the BCECs by this pathway via Concentrative nucleoside transporter 2 and 
Equilibrative nucleoside transporter 1 and 2 (81,84).  
Many transporters can be found on the BCECs that are essential for nutritional supply 
to the brain. However, in the following sections two nutrient transporters, GLUT1 and 
Cluster of Differentiation 98 Heavy Chain (CD98hc), will be highlighted, due to their 
importance in the thesis’ studies.  
GLUT1  
Glucose is the main energy source of the brain and is primarily transported across the 
BBB by GLUT1 (Slc2a1) (77,85). GLUT1 is a 12 transmembrane-spanning α-helices 
(86), that functions as a uniporter transporting glucose down the concentration 
gradient. As glucose concentration is lower in the brain compared to blood plasma, 
glucose will be transporter from blood to brain (81). Expression of this transporter is 
particularly high in the BCECs compared to endothelial cells elsewhere in the body 
(87) and it is notably one of the most abundantly expressed proteins in BCECs (88). 
GLUT1 is expressed on both luminal and abluminal membranes (89) of the BCECs 
and the level of expression is regulated in accordance to the brains metabolic needs 
(90) (see Figure 3). However, there is generally a higher expression on the luminal 
side (91). GLUT1 displays the highest expressional level of solute carriers in human 
BCECs (92) and its expression seems to be both transcriptional and post-
transcriptionally regulated (86,93,94). Due to its high expression in the BCECs, 
GLUT1 has been seen as a potentially suitable target for drug delivery. 
CD98hc 
CD98hc (SLC3A2) is an intracellular amino acid transporter and integrin signaling 
enhancer that belongs to the solute carrier-mediated transporter family (95). It forms 
a heteromeric amino acid transporter with e.g. LAT1 (96,97) that transports large 
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neutral amino acids and various drugs such as L-dopa and valproic acid (VPA) across 
the BBB (97,98). CD98hc knockout fibroblasts were unable to survive in standardized 
cell culture due to ferroptosis and it was established that CD98hc was crucial to 
control oxidative stress and reactive oxygen species (99). Whether CD98hc 
contributes to similar mechanisms in the BCECs is unknown. CD98hc may also help 
regulate glucose metabolism through interaction with GLUT1 (100). A great deal of 
the research on CD98hc has been conducted in connection with cancer. It has been 
suggested as a therapeutic target as cancer cells upregulated the expression of CD98hc 
(101) and the level of CD98hc expression correlates with progressive or metastatic 
tumors (102,103). Exactly why cancer cells upregulated their expression of CD98hc 
is controversial but it could be due to metabolic demands of the tumor (101). CD98hc 
has furthermore been suggested as a target to inhibit T-cells in autoimmune diseases 
as loss of CD98hc prevents disease development in MS (104). 
RECEPTOR-MEDIATED TRANSCYTOSIS 
Receptor-mediated transcytosis (RMT) is needed when transporting macromolecules 
across the BBB (105). This type of transport requires a specific receptor to be present 
at the luminal side of the BCECs (see Figure 2). In theory, binding of a ligand to its 
cognate receptor will trigger an invagination of the plasma membrane, forming a 
vesicle containing the ligand and receptor (106). The vesicle is then transported across 
the cytoplasm to be exocytosed on the abluminal side where the receptor and 
macromolecule will separate (14). However, there is some disagreements on exactly 
how RMT occurs. Currently, receptor-mediated transport is the most promising 
approach for drug delivery to the brain. Among the macromolecules that are possibly 
transported by RMT are: transferrin that is transported with transferrin receptor 1 
(TfR1), melanotransferrin transported with melanotransferrin receptor, amyloid-β 
transported with receptor for advanced glycation end products (107), and insulin 
transported with insulin receptor (14). The following section will focus on transferrin 
receptor 1 (TfR1) due to its application in the thesis’ studies.  
TfR1 
TfR1 (TFRC) is a transmembrane glycoprotein that consists of two identical subunits 
of 90 kDa in humans (108). It promotes uptake of transferrin bound iron and is 
expressed on the surface of most cells (108). TfR1 binds to transferrin, which is one 
of the most abundant plasma proteins found in humans. Only a third of the transferrin 
molecules found in plasma are saturated with iron (called holo-transferrin), where the 
remainder functions as a buffer should the iron concentration increase, thereby 
preventing the toxic accumulation of non-transferrin bound iron (108). Iron has an 
essential part in vital physiological functions such as DNA synthesis and repair, 
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oxygen transport and cell division (109–114). Iron can exist in two forms in the blood, 
as ferrous iron (Fe2+) and ferric iron (Fe3+), and its activity in biochemical reaction is 
dependent on the electron transfer (109,114). Iron can participate in redox reactions, 
also known as Fenton reaction, when it reacts with hydrogen peroxide generating toxic 
free radicals that can cause damage to lipids, proteins and DNA (108,114). Therefore, 
to limit free extracellular iron it is bound to transferrin that carries iron in its oxidized 
and non-toxic form (108,115). Excess intracellular iron that is not essential for 
metabolic purposes is oxidized and stored in the iron storage protein, ferritin 
(108,116).  
The exact mechanism of how transferrin-bound iron is transported across the BBB 
remains a source of uncertainty with various hypotheses prevailing, including 
transport via endocytotic or transcytotic pathways (117). The two transport pathway 
hypotheses are based on the presence or absence of divalent metal transporter 1 
(DMT1) in BCECs, but conflicting results have been reported on this matter (117). In 
both pathways, iron import is initiated by binding of holo-transferrin to TfR1, which 
is located on the luminal membrane of the BCECs. In the transcytosis pathway, the 
holo-transferrin-TfR1 complex is transported via endosomes through the BCECs and 
released directly into the brain. In the endocytosis pathway, the holo-transferrin-TfR1 
complex is internalized within the endosome and ferrous iron is then released through 
DMT1 (116). Iron is subsequently exported from the BCECs into the brain 
parenchyma through the only known iron exporter ferroportin (12,110,117,118). 
Accumulating evidence suggests that the transferrin molecule and the TfR1 do not 
transcytose into the brain, and that iron is released from its binding to transferrin inside 
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1.3. STRATEGIES TO TARGET THE BLOOD-BRAIN BARRIER 
It is important to develop new and more efficient strategies to deliver therapeutics to 
the brain as the BBB hinders transport of most macromolecules. At this given 
moment, not a single recombinant protein that crosses the intact BBB is approved for 
treatment of neurodegenerative diseases (5). Pharmaceutical companies have been 
developing therapeutics for treating brain disorders for decades, and many of these 
have been promising in preclinical models but failed in clinical trials (108). A 
potential explanation is that drug development within pharmaceutical companies has 
failed to ensure adequate drug delivery of potentially novel drugs (5). This is a 
concerning fact given that the prevalence of neurodegenerative diseases increase 
every year.  
The many challenges of delivering drugs to the brain include: modification of the drug 
in the bloodstream by enzymes and other proteins, instability of the drug, low 
transport to the brain as it often accumulates in lungs or liver, highly selective BBB 
and limited specific transporters unique to the BCECs that can be used as targets (7).   
Almost all macromolecular drugs and 98% of small molecular drugs (<400 Da) are 
unable to cross the BBB (7). There are some physical and chemical properties that 
favor transport of small molecules across the BBB. Lipinski originally described these 
for transport across the gastrointestinal barrier, known as Lipinski´s “rule of five” 
(119). However, Goldberg has modified the original “rule of five” to better fit the 
BBB (120). There he states that molecules should: have a weight under 400 Da, have 
a calculated logP less than five, a fewer than three hydrogen bonds and less than seven 
hydrogen bond donors (92,120). Around 70% of all FDA approved CNS drugs fit the 
model described above (92,121) but even though a drug fulfills all the aforementioned 
requirements does not guarantee BBB passage (92). Even though the BBB does not 
deny all larger molecules entry to the brain, only around 0.1-0.2% of the drug serum 
concentration is likely to be transported via nonspecific transcytosis (122). Multiple 
strategies have therefore been generated in order to deliver therapeutics to the brain.  
Targeted drug delivery systems usually consists of three entities. The first one is the 
cargo, which is the therapeutic part and can consist of small molecules, nucleic acids, 
peptides, antibodies and more. The second is the targeting ligand, which can be any 
molecule that will bind the target receptor or transporter on the target organ. The third 
is a linker between the ligand and cargo (123).  
The broad field of targeted delivery will not be discussed in detail, as it is beyond the 
scope and aims of the thesis. The following section will focus on strategies that have 
utilized ligands that bind to TfR1, GLUT1 and CD98hc due to their application in the 
thesis’ studies. 
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TARGETING THE TRANSFERRIN RECEPTOR, GLUT1 AND CD98HC 
Three molecular targets that are enriched on the BCECs of the BBB were chosen for 
further investigation in this dissertation (95). The validity of the aforementioned 
targets in regards to drug delivery will be discussed in the following section. 
TfR1 is among the most studied receptors for BBB targeting with publications dating 
back to 1984 (124), but results have been conflicting (3). The reason for TfR1 
popularity as a drug target on BCECs is because TfR1 is highly specific for BCECs 
as it is not found on other endothelial cells in the body (124). This could lead to 
preferential accumulation of TfR1-targeted molecules in the brain (108). Multiple 
drug conjugates targeting the TfR1 have been created as well as different nanocarriers 
e.g. liposomes, polymers, and gold nanoparticles (108). Furthermore, various 
radiolabeled antibodies targeting TfR1 have been shown to accumulate in the brain 
parenchyma (108). A popular approach for drug delivery is the ´Trojan horse´ method 
where therapeutics are fused to a transport vector that consist of either peptide or 
monoclonal antibody (mAb) that binds to a specific receptor on the BCECs. The 
Trojan horse will upon binding, theoretically, undergo receptor mediated transcytosis 
through the BBB (15,125). The Trojan horse method targeting the TfR1 was first 
achieved in the 1990s, where methotrexate was linked to the rat specific OX26. Both 
the antibody and methotrexate bound to the BCECs, and the data even suggested that 
the antibody-drug conjugate crossed the BBB (126). This study proved that small 
molecular drugs could be transported through the BBB using TfR1 targeting. The 
downside was that only 0.3% fraction of injected dose (ID) of methotrexate was 
transported to the brain parenchyma. In regards to transporting larger molecular drugs, 
nerve growth factor linked to OX26 was able to penetrate the BBB (127) and even 
prevent degeneration in a rat Huntington disease model (128) Later, OX26 mAb 
linked to brain derived neurotrophic factor (BDNF) provided neuroprotective effect 
in the hippocampus after ischemia in rats (129). Similarly, OX26 linked to BDNF was 
able to reduce stroke volume due to the targeting system being able to deliver BDNF 
through the BBB (130).  
After discovering that the OX26 antibody was inefficient in mice, the 8D3 and RI7-
217 mAb targeted to the mouse TfR1 were studied. The 8D3 displayed higher uptake 
in the mouse brain with around 3.1% ID compared to 1.6 % ID for Ri7-217 (131). The 
Ri7 mAb, was, however, more selective for the brain as it was not taken up by the 
liver (131). 
Multiple groups have questioned the efficiency of this transport system as the 
antibodies often remain in the BCECs and were therefore not transported further into 
the brain parenchyma (108,132). Fortunately, recent studies show that therapeutic 
antibodies reach greater brain exposure when the affinity to TfR1 is lowered, as it 
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enables dissociation of the antibody from the TfR1 within the endosome (133,134). 
How the Ri7 mAb performs in a dysfunctional BBB, which is a common feature of 
neurodegenerative diseases, has been investigated recently. There was no difference 
in the expression of TfR1 in isolated microvessels from postmortem parietal cortex 
samples of individuals with or without AD. The same was found in isolated murine 
brain microvessels from 12- and 18-month old NonTg and 3xTg AD mice, and the 
uptake of the Ri7 mAb was also similar (135). This emphasizes the validity of Ri7 as 
a transport system not only in healthy subjects, but also neurodegeneration.  
Another transporter that can be used as a target is GLUT1, which is thought to mediate 
transport through carrier-mediated pathway that does not rely on a specific receptor 
but a solute carrier protein. A great example of this type of transport is the transport 
of L-dopa, the precursor of dopamine. It was discovered that L-dopa was able to cross 
the BBB after systemic administration (136) and later revealed that it was transported 
through carrier mediated transport via LAT1 (5,137,138). Unfortunately, as the 
conversion of L-dopa to dopamine does not only occur in the brain, the chronic 
treatment can result in excessive dopamine in the periphery (139). Therefore, 
derivatives of dopamine and L-Dopa have been linked to glucose at the C-3 position. 
As the dopamine derivatives were more active in suppressing symptoms in rats, it was 
suggested that the glycosyl conjugation allowed the drug to cross the BBB, possibly 
through GLUT1 (139), which was confirmed a few years later (140). Multiple drugs 
have been conjugated with glucose in hopes of targeting GLUT1 for BBB penetration. 
An example is D-glucose conjugates of 7-chlorokynurenic acid, which is used to 
produce antidepressant effects in animal models of depression but is unable to cross 
the BBB. The drug conjugate was able to cross the BBB and GLUT1 was suggested 
to be the route of transport (141). GLUT1 does not only affect transport of conjugates 
using glucose, as mannose-conjugated liposomes displayed significantly higher brain 
fluorescence in mice (142). Similarly, BDNF containing liposomes with mannose and 
cell penetrating peptides as ligands displayed a significantly higher astrocyte and 
neuron penetration than unmodified liposomes reaching 7% transport of ID (143). 
Exactly how these liposomes are transported is unknown, but the addition of a ligand 
that targets to GLUT1 has proven quite efficient.  
It was recently discovered by transcriptomic and proteomic profiling, that CD98hc is 
enriched in the BBB (95,144). As it is newly identified as a potential target for BBB, 
there is very little literature on the subject. However, antibodies against CD98hc did 
accumulate in the brain of mice reaching 80-90 times higher levels than the control 
IgG and even 4 to 5 times higher level than the TfR1 targeted antibodies (95,145). A 
bispecific antibody binding CD98hc and β-secretase 1, the enzyme that cleaves 
amyloid precursor protein (APP) and thus increases Aβ plaques formation in AD, 
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reduced the level of Aβ plaques by 30-45% when compared to IgG treated mice (95). 
These results make CD98hc an interesting target to investigate.  
These three targets will be investigated further in the thesis’ studies. TfR1 is the most 
studied target on the BBB where multiple different ligands have been utilized in 
various animal models. GLUT1 is an interesting target due to its abundance in the 
BBB, and has proven efficient in facilitating transport of therapeutics in relatively 
high concentrations. At last, CD98hc is a newly identified target for drug delivery that 
needs further investigation.  
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1.4. THE PATHOLOGICAL BLOOD-BRAIN BARRIER 
Dysfunction of the BBB is associated with both onset and progression of various 
disorders e.g. AD (146), stroke (147), MS (148), traumatic brain injury (149), and 
amyotrophic lateral sclerosis (150). The pathology of these disorders vary, but there 
is a common detrimental effect, which is inflammation. Inflammation in the BBB can 
be caused by systemic inflammation that subsequently affects the BCECs, which can 
mediate changes in pericytes, astrocytes, and even neurons (151). Low grade systemic 
inflammation, defined as slightly increased level of C-Reactive Protein (152), affects 
around 40% of people residing in Western countries (153). This low grade 
inflammation causes damage to the BBB (154) and it is therefore extremely relevant 
to understand the effect of continuous systemic inflammation on the BBB. The second 
origin of inflammation in the BBB is neuroinflammation, which is the inflammatory 
response within the brain and spinal cord in response to injury, trauma, autoimmunity 
or infection (151). Neuroinflammation is primarily driven by microglia that reside 
within the brain, which is further amplified by astrocytes (17,155) and comprises 
response from both the innate and adaptive immune system (156).  
Pathophysiological factors, such as inflammation, increase the permeability of the 
BBB which can cause barrier disruption (157). The term disruption of the BBB is a 
broad term, and the alterations of the BBB can therefore be categorized into disruptive 
and non-disruptive changes (158). In non-disruptive changes, the TJs are intact and 
the alterations of the BBB are functional and usually occur at a molecular level. This 
can include cytokine production by BCECs, up- or down regulation of various 
transporters, and modulation of astrocyte function (158). Disruptive alterations are 
visible at the histological level and include changes in tight junction arrangement, 
degradation of the glycocalyx, endothelial damage, and increased vesicular transport 
(158). The dynamic BBB is not likely to be permanently disrupted early in the course 
of neurodegenerative diseases (159). Hence, it is important to understand the subtle, 
early, non-disruptive changes as well as mild disruptive alterations that happen in the 
BBB. It is believed that inflammation typically precedes the degeneration in neuro-
degenerative diseases such as AD, PD, and MS, which can then progress 
independently of inflammation (155,160). The effect of inflammation on disease 
progression and the BBB in two very different neurodegenerative diseases, MS and 
AD, will be briefly discussed in the following sections.  
MS is a neurodegenerative disease characterized by autoimmune attacks on the myelin 
sheath that result in multifocal lesions throughout the CNS (161,162). What sets MS 
apart from other neurodegenerative diseases is that it usually affects young adults with 
an onset between 20 years and 40 years of age (162) and is currently the second largest 
cause of disability in young adults (163,164). MS is more frequent in women than 
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men, and more common in regions of northern Europe than elsewhere (165,166). The 
breakdown of the BBB is a key event that is present early on in the pathogenesis of 
MS (167). However, barrier leakage is usually only present in new lesions, and not in 
older lesions (168), suggesting that the BBB restores its integrity. The 
pathophysiology of MS is initiated by increased migration of autoreactive 
lymphocytes across the altered BBB, which then activate local glia cells to release 
pro-inflammatory cytokines. The immune system fails to suppress inflammation, 
which enables various immune cells such as autoreactive lymphocytes, monocytes, 
and macrophages to migrate across the BBB and attack myelinated axons (161,169). 
The endothelial cells have an active role in leukocyte adherence and migration due to 
their expression of various adherence molecules, Intercellular Adhesion Molecule 1 
(ICAM-1) and Vascular cell adhesion molecules (VCAM), and are therefore of great 
importance in initiating the immune response in MS (170). The multistep cascade of 
leukocyte trafficking into CNS has been well studied and the so-called intraluminal 
crawling step is dependent on ICAM-1, and the transendothelial migration is 
dependent on ICAM-1 and VCAM (171). The resulting inflammation leads to 
additional migration into the brain of other cell types of the specific and innate 
immune system, including monocytes and macrophages (169). Healthy BCECs 
exhibit low leukocyte adhesion molecule expression compared to endothelial cells 
elsewhere in the body, but increase the expression during neuroinflammation (88).  
AD is a progressive neurodegenerative disorder that is characterized by cognitive 
impairment, which can include memory loss, language deterioration, and emotional 
instability (146). AD is also the most common form of dementia (172) and 
epidemiologists fear that the number of new cases will double every 20 years (173).  
The etiology of Alzheimer´s disease is complex and still not fully understood (174), 
but  has been characterized by accumulation of Aβ plaques and neurofibrillary tangles 
(156). The majority of AD cases is sporadic where early onset usually occurs after the 
age of 65 (175). Autosomal dominant familial AD is thought to account for 1 in 200 
cases and usually presents before the age of 65. The patients usually carry a mutation 
in prenisilin 1, prenisilin 2 or APP gene which all increase the production of Aβ (175). 
However, the accumulation of Aβ alone seems insufficient to generate symptoms 
(174,176). The pathology of AD is highly affected by chronic neuroinflammation that 
is driven by microglia and further enhanced by astrocytes (177). In AD, microglia 
accumulate around Aβ plaques, attain activated morphology and bind to Aβ plaques 
via CD36, toll-like receptor (TLR) 4 and TLR6. This will increase their secretion of 
proinflammatory cytokines and chemokines (178,179). Microglia activation can 
consequently promote astrogliosis (63), where astrocytes become activated in 
response to stimuli. The hypertrophic reactive astrocytes will then accumulation 
around Aβ plaques and escalate scar formation (179,180). The activation of microglia 
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and astrocytes is therefore the main driver of neuroinflammation in AD, which 
contributes to disease progression and severity (179). High cytokine levels have been 
associated with more severe disease progression. As an example have high levels of 
TNF-α in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment 
shown to increases their risk for conversion to the dementia stage of the disease (181). 
Increased expression of adhesion molecules can, similarly to MS, affect the 
neuroinflammation in AD. Expression of both ICAM-1 and VCAM is increased in the 
brains of Arc/SweAβ and 5xFAD mouse models of AD (177,182,183). Similarly, both 
ICAM-1 and VCAM are increased in the CSF of AD patients (184).  
Even though MS and AD have different pathologies and etiologies, neuro-
inflammation has a severe effect on the disease progression. Both diseases present 
with increased microglial and astrocyte activation, increased cytokine secretion and 
higher adhesion molecule expression by the BCECs. The aforementioned factors are 
also present in other neuroinflammatory diseases such as PD and Huntington´s disease 
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1.5. EPIGENETIC REGULATION AT THE BLOOD-BRAIN 
BARRIER 
Epigenetics is the study of the cells transcriptome rather than the DNA itself, and has 
been defined as heritable changes in gene expression that are stable between cell 
divisions and even between generations without involving changes in the DNA 
sequence (186,187). All cells in a given organism contain the same genetic material, 
but the biology and function of cells and tissues vary due to a variation in the 
transcriptome (186,188). In other words, epigenetic factors regulate how and when 
genes are expressed (186,189,190). These epigenetic changes are dynamic, which 
may make it possible to alter a disease state by manipulating the expression of 
receptors, molecules or enzymes that are involved in the pathogenesis or a response 
to a given stimuli (186,187).  
Epigenetic regulation can occur on the DNA itself, or on histones as post-
transcriptional regulation, which include acetylation, methylation, phosphorylation 
(191). DNA methylation is a rigid form for transcriptional silencing that results in a 
long term alteration of the gene expression, and is currently the best characterized 
covalent modification of DNA (192–194). Actively transcribed genes do therefore 
contain low DNA methylation percentage and vice versa (188,194). DNA methylation 
is the addition of a methyl group to the 5-carbon position of cytosine catalyzed by 
methyltransferases (188,194,195). A more flexible form of transcriptional regulation 
are post-translational histone modifications where histone H3 is modified by 
acetylation, methylation, or phosphorylation (196). Histone acetylation impacts the 
folding of histones, where hypoacetylation driven by histone deacetylase forms a 
highly compact chromatin and hyperacetylation disrupts nucleosome folding, thereby 
increasing the accessibility to binding of transcriptional factors resulting in enhanced 
transcription (197). There are multiple approved HDAC inhibitors that promote 
acetylation of histones and consequently transcription of multiple genes (198), one of 
which is VPA (199). VPA is a FDA approved anti-epileptic drug that can be used as 
a mood stabilizer, and to treat both migraine and psychiatric disorders (200). It is 
generally well-tolerated and has sparked interest as treatment in other areas. The effect 
of VPA on the brain is versatile as it can increase the activity of the inhibitory 
neurotransmitter Gamma-Aminobutyric acid (194,201). In addition, VPA prevents 
BBB disruption following a subarachnoid hemorrhage (202), lessens BBB disruption 
after transient focal cerebral ischemia (194,203), and reduces neuroinflammatory 
cytokines in late stages of AD Tg6779 murine model (204). VPA has especially 
gained popularity in traumatic brain injury research where its neuroprotective 
properties are credited upregulation of several genes within certain pathways 
(194,205–207). 
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Epigenetic alterations can occur throughout the entire lifespan, and there is even signs 
of some regional heterogeneity present in the BCECs of the CNS, where some regions 
such as choroid plexus, pineal gland, and median eminence of the hypothalamus have 
fenestrated capillaries that lack BBB properties (17,18).  
The BBB has been shown to be affected by simple things such as exercise and diet 
(17). A high-fat diet has been shown to increase BBB permeability, neuro-
inflammation, and production of reactive oxygen species in mice (208). Furthermore, 
a mouse model of diet-induced type II diabetes displayed an increase in BBB 
permeability (209) and so did a study carried out on insulin-resistant mice (210). The 
lifestyle of an animal can affect the function of the BBB, which has been shown to 
upregulate ketone transporters in hibernating animals in order to survive (211). All of 
these alterations of the BBB due to various stimuli may be epigenetically regulated.  
GLUT1 has been shown to be epigenetically upregulated in the BBB during fasting 
mice via histone modifications (212). This was the only published data, to the author’s 
best knowledge, on epigenetic regulation of GLUT1 in the BBB to date, but there are 
some other implications for epigenetic regulation. As an example, GLUT1 expression 
is higher in adult mice brain compared with neonatal brain (213), which could indicate 
a layer of epigenetic regulation dependent on age. Similar results were found in 
isolated brain capillaries from newborn rats compared to 56 day postnatal rats (214). 
Conversely, GLUT1 is downregulated in patients with AD in multiple studies (215–
217). Recent study on mice has shown that endothelial-specific loss of GLUT1 leads 
to progressive neuronal loss and CNS inflammation (213), which are both hallmarks 
of neurodegenerative diseases.  
Alteration in the epigenetic landscape of adhesion molecules of BCECs have been 
found in response to inflammation in various neurodegenerative diseases. 
Hypermethylation of ICAM-1 was found in MS patients during the remission phase 
in cell free plasma DNA (218). That means, that ICAM-1 expression is inhibited 
through increased methylation following a relapse phase (196,218). Similarly, both 
ICAM-1 and VCAM expression in rodent model of stroke seems to be correlated with 
the activity of histone lysine methylases and demethylases (219).  
Unfortunately, very few published studies have investigated the epigenetic regulation 
of various transporters in the BBB during neuroinflammation or other pathology 
related to neurodegenerative diseases. In order to achieve greater accumulation of 
therapeutics in the brain, it is crucial to understand the dynamic alteration in BCECs 
surface transporters in response to various stimuli. Downregulation of otherwise 
suitable targets, in response to e.g. inflammation, could affect the transport of an 
otherwise potent drug. 
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CHAPTER 2. MODELSYSTEMS AND 
METHODS  
2.1. LIPOPOLYSACCHARIDE RODENT MODELS 
Multiple rodent models have been generated to investigate the complex nature of 
systemic inflammation (220). These models can be divided to three main groups: 
exogenous administration of endotoxins such as lipopolysaccharide (LPS), exogenous 
administration of viable pathogens such as Escherichia coli, and disruption of 
endogenous protective barrier e.g. with cecal ligation. A clear advantage of using LPS 
is that it can in addition to causing systemic inflammation also induce neuro-
inflammation (221–225) and the focus will therefore be on LPS in the following 
sections.  
INFLAMMATION AND NEUROINFLAMMATION USING LPS  
The LPS models are an important and widely used animal model for 
neuroinflammation as this systemically induced inflammation is able to induce 
cytokine production in the brain (221). LPS is an endotoxin that is found in the outer 
membrane of gram-negative bacteria that binds to TLR4 with the help of LPS binding 
protein and the endotoxin receptor CD14 (226). TLR4 is expressed in immune cells, 
such as monocytes and macrophages, but also in endothelial cells and astrocytes (226–
229). Binding will initiate the production of pro-inflammatory cytokines, including 
IL-1β, IL-6 and TNF-α (230). As LPS does not pass the BBB, the inflammatory effect 
is thought to be mediated to the brain by one of these potential routes: through 
activation of the blood-cerebrospinal fluid barrier in choroid plexus, by active 
transport of pro-inflammatory cytokines through the BBB or direct activation of 
BCECs that express TLR4. Even though the exact mechanism of how systemic LPS 
creates neuroinflammation remains to be elucidated, the active transport of pro-
inflammatory cytokines from the periphery has been shown to mediate neuro-
inflammation, and secretion of TNF-α seems to be crucial (231,232). Even just a 
single intra peritoneal (i.p) injection of LPS resulted in elevated TNF-α levels within 
the brain, and remained high for 10 months whereas the systemic inflammation was 
cleared within a week (231). Why pro-inflammatory cytokines are found in the brain 
so long after the systemic inflammation has been cleared is unknown.  
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PARAMETERS THAT INFLUENCE THE OUTCOME OF THE LPS MODEL 
There are multiple discrepancies between results from various laboratories to which 
inflammatory cytokines are produced in the periphery upon LPS stimulation. This can 
be explained by the numerous experimental details that vary between laboratories e.g. 
the strain and age of mice, gender, administration route, concentration and type of 
LPS, as well as time of sacrifice after last LPS injection (221,225).  
Multiple strains of mice have been used when inducing inflammation with LPS. 
Female BALB/c and C57BL/6 mice have been investigated in context of which 
inflammatory cytokines peritoneal macrophages produce upon intraperitoneal (i.p) 
injections of LPS (233). Cytokine measurements exhibited that C57BL/6 
macrophages produced more IL-17, IL-10 and interferon-gamma whereas BALB/c 
macrophages produced more TGF-β and IL-4 (233). Another study found that the 
inflammatory response was higher in male BALB/c mice than in male C57BL/6 mice 
(234).  
Gender and age of mice can also have an effect on how the animals respond to LPS 
injections (235,236). It has been demonstrated that male mice generally respond more 
severely than female mice after LPS injections. Males were immobile 24 hours after 
LPS injections and displayed depressive like behavior, whereas the females displayed 
sickness like behavior. Moreover, the males had significant hippocampal apoptosis 
and various markers of oxidative stress increased (237). The females, however, 
increased their expression of antioxidant metallothionein (237) which could have 
protective properties. Another study found that only male mice increased their TNF-
α brain expression after LPS treatment (232). It has even been reported that exposure 
to inflammation intrauterine causes different reactions between male and female 
fetuses, where male offspring display higher cytokine response with increased IL-1β 
and TNF-α whereas females did not (238). There are many possible explanations to 
the gender-based differences in immune response and the answer is likely complicated 
and multi-factored (237,239,240). Additionally, adult mice have been shown to 
increase their pro-inflammatory cytokine production more than pubertal mice, where 
pubertal mice secreted more anti-inflammatory cytokines after acute LPS treatment 
(241). It has been demonstrated that microglia response increases during aging in 
wild-type C57BL/6 mice after LPS injection in the hippocampus (242). Similarly, 
another study has shown that older mice (22 months old) increase their expression of 
TNF-α, IL-1β, and IL-10 protein levels in plasma more than younger mice (6 months 
old) but the younger C57BL/6 mice displayed higher levels of the aforementioned 
cytokines in the brain after a single dose of maximally tolerated dose of LPS (243). 
LPS can be isolated from various bacterial strains, which can cause the immune 
system to act differently dependent on the signal transduction pathways that are 
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activated (244). Strains that are often used include Escherichia coli, Salmonella 
typhimurium, S. minnesota, and Neisseria meningitidis (244). This can explain the 
difference in the cytokine profile measured between laboratories, even though the 
concentration of LPS and duration of stimuli was the same. How LPS is administrated 
can also influence the results. LPS can be administrated systematically i.v, i.p, as well 
as intracranial (245,246). In general, i.v and i.p injections produce similar 
inflammatory responses (247–249). When administering a single dose of LPS 
systematically, the concentrations vary from 0.33 mg/kg to 10 mg/kg (250–252). 20 
mg/kg is a lethal dose for BALB/c mice (253) and concentrations between 15 mg/kg 
and 27 mg/kg are lethal in C57BL/6 mice (254–256). Additionally, LPS has been 
administered multiple times, even multiple times a day in some models with two or 
three doses within 24 hours (250). LPS has, furthermore, been administered daily for 
a week, where the doses are generally between 0.25 mg/kg (257,258) and 1.5 mg/kg 
(259). When looking at messenger RNA (mRNA) expression of various genes, the 
time of sacrifice after administration of LPS can determine whether you find an up- 
or downregulation of the target gene. One study using C57BL/6 mice found that TNF-
α was upregulated in the hippocampus 3 hours after i.p administration of LPS, but 
returned to baseline after 6 hours. 
The objective of the LPS animal study was to investigate the effect of systemic 
inflammation and neuroinflammation on the expression of both adhesion molecules 
as well as receptors and nutrient transporters present on the BCECs suitable for 
targeted drug delivery. It has been shown that systemic inflammation, provoked by i.p 
injections of LPS for seven consecutive days where the mice were sacrificed a week 
after last injection, can induce an increase in multiple cytokines within the brain (258). 
The same authors displayed a clear increase in activation of microglia in the 
hippocampus as well as cognitive impairment in the LPS treated animals (258). Due 
to the general difference in reported results when inducing inflammation or 
neuroinflammation with LPS, we chose to replicate the aforementioned study in hopes 
of recreating the neuroinflammatory environment.  
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2.2. IN VITRO MODELS OF THE BLOOD-BRAIN BARRIER 
Due to the complexity of studying various molecular interactions in the BBB in vivo, 
multiple in vitro models have been constructed to study cellular interaction, molecular 
alterations in response to insult, and transport of numerous molecules. Many in vitro 
BBB models have been developed using primary cells isolated from multiple species, 
including porcine, mouse, rat, and primate, as well as cell line models, including the 
immortalized bEND3 and HBMEC cell models (260). Primary BBB models of rat and 
mouse origin are well characterized, easy to obtain and commonly the first choice for 
pre-clinical studies (260). 
An optimal in vitro BBB model would replicate all aspects of the human brain 
endothelium, but such a model has not been generated simply because cells that have 
been taken out of their natural microenvironment and cultured in relative simple 
media will behave differently (4). Among basic characteristics an BBB in vitro model 
is required to comprise are low passive paracellular permeability, high expression of 
tight junction proteins and functional transporters, and maybe most importantly the 
barrier needs to be reproducible with similar characteristics (261). Immortalized cell 
cultures are often utilized as they are more easily obtainable than primary cells (262). 
Nevertheless, immortalized cell lines, as well as all other cells, are known to lose 
many of their in vivo characteristics when cultured for multiple passages (261). 
Primary BBB models are therefore an optimal choice as they resemble the in vivo 
condition more (260).  
A popular setup for an artificial BBB is the so-called Transwell system, which can be 
created using both primary and immortalized cells. A Transwell system creates a 
diffusion system that consists of a semipermeable membrane separating the vascular 
side from the parenchymal side in an upper and lower compartment (263). There are 
multiple ways of setting up a co-culture Transwell system. BCECs are grown in a 
culture insert and make up the luminal side of the barrier model (see Figure 3). Glia 
cells that can consist of astrocytes, pericytes or mixed glia, are then cultured in the 
bottom of the well and make up the abluminal side of the barrier (see Figure 3). It is 
possible to establish the barrier as so-called contact or non-contact cultures, which 
refers to whether the glia cells are in direct contact with the BCECs on the other side 
of the filter insert, or if they are cultured in the bottom of the well. (264). As mentioned 
earlier, it is important for the model to display low paracellular transport. The 
Transendothelial Electrical Resistance (TEER) is a method of assessing the electrical 
resistance across a cellular monolayer, which indicates the paracellular water flow and 
pore size of tight junctions, thereby evaluating barrier integrity of the Transwell 
system in real-time without damaging the barrier (265,266). Astrocytes increase the 
TEER when grown in co-culture with BCECs (see Figure 3), as they induce TJ protein 
expression through secretion of neurotrophic factors such as Glia-cell derived 
CHAPTER 2. MODELSYSTEMS AND METHODS 
41 
neurotrophic factor, basic fibroblast growth factor, and transforming growth factor 
beta 1 (13,267,268). Due to the clear advantages of incorporating astrocytes or mixed 
glia in the Transwell system, the current thesis will utilize a non-contact co-culture 
model containing mixed glia cells for its studies (see Figure 3).   
 
Figure 3: Transwell system displaying a non-contact co-culture system where brain 
capillary endothelial cells (BCECs) are cultured on hanging inserts, making up the 
luminal side of the barrier. The mixed glia cells are cultured in the bottom of the well, 
making up the abluminal side of the barrier. The immunocytochemistry illustrations 
display BCECs (on the left) stained with ZO-1 and Dapi, and the mixed glia culture 
(on the right) stained for GFAP to identify astrocytes and Cd11b to identify microglia, 
as well as Dapi. The scale bar is 20 µm.  
As the most common feature of neurodegenerative diseases is neuroinflammation 
(269), it would be beneficial to have an in vitro model that simulates many of the 
characteristics, such as activation of microglia and astrocytes, increased cytokine 
secretion from glia and alteration of adhesion molecules on the BCECs. However, the 
complex nature of neuroinflammation has not yet been simulated sufficiently in vitro. 
There are multiple primary cell inflammatory in vitro models utilizing LPS as a 
stimulant. However, LPS is usually added directly to the BCECs whilst the barrier is 
assembled (270–274) and as BCECs are more sensitive to LPS stimulation than 
astrocytes (275), this will result in a disruptive BBB. LPS stimulated BCECs will lose 
expression of TJs, the glycocalyx will degrade, and the paracellular permeability will 
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increase (158,275,276). Astrocytes and other microglia respond differently to LPS 
stimuli than BCECs, which include increased expression of pro-inflammatory 
cytokines (158,277,278). LPS itself does not take any part in neuroinflammation, and 
it is therefore not optimal to stimulate the BCECs with LPS directly. LPS induces a 
broad immunological response, which can serve as a model for neuroinflammation. 
Others have stimulated BCECs, astrocytes or mixed glia with a specific cytokine 
(279), but that produces a limited inflammatory response that is an oversimplification 
of the complicated nature of neuroinflammation. An improved neuroinflammatory in 
vitro model is therefore needed in order to investigate molecular alterations on a 
cellular level.   
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CHAPTER 3. THESIS OBJECTIVES 
The objectives of this dissertation have been to understand how the expression of the 
promising molecular drug targets TfR1, Glut1, and CD98hc, by BCECs can be 
affected by systemic inflammation and neuroinflammation, as well as to investigate 
whether their epigenetic manipulation is achievable. In order to accomplish this, four 
different studies were conducted. Study I was a “proof of concept” for study II, both 
focusing on epigenetic manipulation of different molecules related to iron transport at 
the BBB, i.e. ferroportin and TfR1. Study III focused on creating an in vitro BBB 
model that simulated neuroinflammation, whereas study IV compares the effects of 
neuroinflammation on the expression of the molecular targets CD98hc, Glut1 and 
TfR1 in vivo and in vitro.   
Study I:  
Aim: To investigate if epigenetic regulation of ferroportin enables increased iron 
efflux in cultured BCECs.  
Objectives: To treat primary rat BCECs cultures with two different histone 
deacetylase inhibitors (HDACi) to enhance ferroportin expression. To analyze the 
expression of ferroportin at the transcriptional, translational and functional level.   
 
Study II:  
Aim: To investigate whether HDACi epigenetically increases the expression of TfR1, 
Glut1, and CD98hc in BCECs. 
Objectives: To study the expression of TfR1, Glut1, and CD98hc by mouse BCECs 
in vitro and in vivo following HDACi treatment. Furthermore to investigate if HDACi 
treatment can increase the surface availability of TfR1 and possibly leading to 
increased in vivo uptake at the BBB of anti-TfR (Ri7)-conjugated gold nanoparticles. 
 
Study III:  
Aim: To investigate if an in vitro model consisting of primary mouse BCECs and 
mixed glia can be modified to allow reactive glia to subsequently influence the BBB.  
Objectives: To establish an in vitro model of the BBB where inflammation is induced 
in mixed glia cells using LPS. How the reactive mixed glia affect the BCECs will 
subsequently be investigated.  
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Study IV:  
Aim: To investigate possible changes in expression of the suitable drug targets TfR1, 
Glut1, and CD98hc by the BCECs in vivo and in vitro following inflammatory stimuli.  
Objectives: C57BL/6JRj mice will be injected with LPS in a different dose regiment 
to obtain neuroinflammatory changes in the brain with the presence of activated 
microglia, possible migration of macrophages into the brain, as well as activated 
BCECs seen by increased expression of the cell adhesion molecules ICAM-1 and 
VCAM. The expression of drug delivery targets by the BCECs will be investigated 
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Abstract 
Ferroportin plays an essential role for iron transport through the blood-brain barrier 
(BBB), which is formed by brain capillary endothelial cells (BCECs). To maintain the 
integrity of the BBB, the BCECs gain support from pericytes and astrocytes, which 
together with neurons form the neurovascular unit (NVU). The objectives of the 
present study were to investigate ferroportin (Fpn) expression in primary cells of the 
NVU and to determine if Fpn expression is epigenetically regulated. Primary rat 
BCECs, pericytes, astrocytes, and neurons all expressed ferroportin mRNA and 
protein at varying levels, with BCECs exhibiting the highest expression of Fpn, 
peaking when co-cultured, but examined separately, from astrocytes. Conversely, Fpn 
expression was lowest in isolated astrocytes, which correlated with high DNA 
methylation in their Slc40a1 promoter. To provide further evidence for epigenetic 
regulation, mono-cultured BCECs, pericytes, and astrocytes were treated with the 
histone deacetylase inhibitors valproic acid (VPA) and sodium butyrate (SB), which 
significantly increased Fpn and ferroportin protein in BCECs and pericytes. 
Furthermore, 59Fe export from BCECs was elevated after treatment with VPA. In 
conclusion, we present first time evidence stating that Fpn expression is epigenetically 
regulated in BCECs, which may have implications for inadvertent pharmacological 
induction of iron transport through the BBB. 
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The transferrin receptor plays an essential role for iron transport through the blood-
brain barrier (BBB) formed by brain capillary endothelial cells (BCECs). To maintain 
the integrity of the BBB, the BCECs gain support from pericytes and astrocytes, which 
together with neurons form the neurovascular unit (NVU). The objectives of the 
present study were to investigate the expression of transferrin receptor (TfR), Cluster 
of Differentiation 98 Heavy Chain (CD98hc) and glucose transporter 1 (Glut1) in 
BCECs and to determine if their expression is epigenetically regulated. The 
expression of these targets were investigated both in vitro and in vivo following 
treatment with the histone deacetylase inhibitor (HDACi) valproic acid (VPA). Mice 
were injected with VPA followed by analysis of isolated brain capillaries, and the 
capillary depleted brain samples, which revealed expressional increase in mRNA and 
protein content. To evaluate the surface availability of the epigenetically enriched TfR 
and the ability to target it for transport of large molecules, anti-TfR (Ri7)-conjugated 
gold nanoparticles were studied for uptake and transport into the brain following 
intravenous injection in VPA treated mice. Estimating the antibody uptake by measure 
of gold using ICP-MS revealed equal uptake in brains of VPA and un-injected mice, 
which indicates that the increase in overall TfR protein expression in BCECs consists 
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Abstract 
Neuroinflammation is a common feature in neurodegenerative diseases and the main 
reason for detrimental alteration in the blood-brain barrier (BBB). However, no 
standardized neuroinflammatory in vitro model that preserves the integrity of the BBB 
has been established. Therefore, we have generated a novel transwell system, where 
only the mixed glia cultures were stimulated with lipopolysaccharide (LPS) for three 
hours, after which the LPS was removed and the BBB model established. The brain 
capillary endothelial cells (BCECs) were, therefore, only affected by cytokines and 
other inflammatory factors released from the stimulated mixed glia culture. The 
expression and secretion of various cytokines from mixed glia were measured using 
RT-qPCR and Meso Scale Discovery analysis. The effect of the inflammatory stimuli 
on BCECs was investigated by measuring the integrity of the BCECs by evaluating 
alterations in the transendothelial and paracellular resistance. Immunocytochemistry 
was utilized to investigate the composition of the mixed glia culture as well as the 
BCECs tight junction protein arrangement and expression of adhesions molecules 
Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular cell adhesion protein 1 
(VCAM). Glia cells showed significant upregulation of mRNA expression of 
interleukin 6 (IL-6), interleukin 1β (IL-1β), and Tumor necrosis factor α (TNF-α). 
Secretion of proinflammatory cytokines was significantly higher following LPS 
stimulation and the morphology of astrocytes changed to a more reactive form. The 
expression of adhesion molecules ICAM-1 and VCAM increased in the BCECs 
following co-culture with LPS stimulated mixed glia cells, and the arrangement of 
tight junction molecules was altered. In conclusion, the model displays 
neuroinflammation and activation of glia cells that endures even after stimuli is 
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Abstract 
A common feature among neurodegenerative diseases, neuroinflammation denotes 
the main reason for detrimental alterations of the blood-brain barrier (BBB) integrity. 
The BBB keeps harmful substances out of the brain but simultaneously hinders the 
transport of therapeutics to the brain parenchyma. The presently available portfolio 
of small, synthetic drugs do not fulfill the demands for treatment of neurodegenerative 
disorders, which have justified research in transport of large molecules of biological 
nature to access the brain. The transport of the latter across the BBB is clearly 
enhanced when simultaneously targeting receptors or transporters expressed at the 
BBB. In vivo and in vitro studies were performed to study the impact of 
proinflammatory stimuli on the expression of targetable molecules on brain capillary 
endothelial cells (BCECs). Mice were injected intraperitoneally with 0.75 mg/kg or 
1.25 mg/kg lipopolysaccharides (LPS) for seven consecutive day, and euthanized 
either 24 hours later or 7 days after last injection. Meso Scale Discovery analysis was 
carried out on plasma and brain homogenate to measure the cytokine levels of ten 
pro- and anti-inflammatory cytokines. To further evaluate neuroinflammatory effects, 
brains were stained for microglia marker CD11b, adhesion molecules Intercellular 
Adhesion Molecule 1 (ICAM-1) and Vascular cell adhesion molecules 1 (VCAM1). 
Furthermore, a non-contact co-cultured BBB Transwell system was prepared, where 
mixed glia cells were stimulated with LPS. The expression of Cluster of Differentiation 
98 Heavy Chain (CD98hc), Glucose transporter 1 (Glut1) and Transferrin receptor 1 
(TfR) was investigated in vivo and in vitro using immunolabeling. LPS-treated mice 
increased their expression of IL-1β and IL-10 in plasma, and IL-1β, IL-2 and KC/GRO 
in brain. The animals did show clear signs of neuroinflammation with increased 
CD11b, ICAM-1 and VCAM immunoreactivity. However, there was not seen a drastic 
downregulation of CD98hc, Glut1 or TfR in response to neuroinflammation.   
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CHAPTER 5. DISCUSSION 
This chapter will discuss the findings of Study I-IV in context of existing literature. 
Contrary to the discussions presented in each of the individual studies, the focus here 
will be on discussing the findings as a whole. The first part of the thesis (Study I and 
II) investigated whether it was possible to use epigenetics to upregulate the expression 
and surface availability of suitable targets for drug delivery in young and healthy mice. 
Study I served primarily as a simplified “proof of concept” for study II, investigating 
the expression of the only iron exporter ferroportin in vitro (194). The second part of 
the thesis (Study III and IV) focusses on the neuroinflammation that is present in 
neurodegenerative diseases, and how it could affect the expression of suitable drug 
targets on the BCECs. Due to a lack of suitable in vitro model for neuroinflammation, 
Study III was devoted to establishing such a model and study IV investigated how 
expression of targets on the BCECs altered during neuroinflammation both in vitro 
and in vivo.  
The dissertation discussion will be divided into two parts reflecting the two different 
topics of the thesis, the first focusing on targeted delivery and epigenetics, and the 
second on neuroinflammation.  
5.1. IS TARGETED DRUG DELIVERY NECESSARY TO OBTAIN 
BLOOD-BRAIN BARRIER TRANSPORT IN ORDER TO 
TREAT NEURODEGENERATIVE DISEASES?  
When looking at the limited progress in treating neurodegenerative diseases over the 
last decades it is hard not to be discouraged. Fortunately, there has been some success 
in treatment of neurodegenerative diseases. MS stands out in that regard, as multiple 
different therapeutics have been successful in slowing down the disease progression. 
Even though MS is categorized as a neurodegenerative disease, the treatment 
approach is actually not confined to the brain. The effective strategies include: 
immune modification in the periphery by retaining naive memory T cells in the lymph 
nodes or lymphatic tissues with fingolimod, reducing the number of cytotoxic T cells 
in the blood with dimethyl fumarate or depleting circulating autoreactive B and T 
lymphocytes with cladribine (280,281). Other approaches focus on inhibiting the 
leukocyte migration into the brain by blocking interaction with VCAM on BCECs 
with e.g. natalizumab (282,283). All of these treatment options are therefore not 
dependent on transport across the BBB.   
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When it comes to developing effective therapies for neurodegenerative diseases that 
are reliant on transport to the brain parenchyma, no major breakthrough has been 
achieved. It is surprising that after decades of research and hundreds of clinical trials, 
there still is no approved treatment that can successfully slow down the progression 
of AD. Only 170 drugs are currently in development for AD, which may seem like a 
lot, but compared to 433 for diabetes and 6833 for malignant neoplasms, once 
perspective might change (284). It is maybe less surprising when the estimated failure 
rate of 99.6% in AD drug development is taken into account (284). But why do 
promising therapeutics that yield great efficacy in preclinical models fail to provide 
therapeutic effect in clinical trials? There are many possible reasons, but one could be 
that most of the drugs did not provide sufficient transport into the brain parenchyma. 
Delivering targeted therapeutics to the brain is no easy task as transporting the drug 
to the BCECs is just the first step. Successful drug delivery of therapeutics need to 
fulfill two criteria: they need to be efficiently targeted and delivered to the 
pathological site within the brain, and then be able to release the therapeutic drug in 
appropriate amount to elicit a pharmacological response without significant side 
effects (285).  
It is therefore critical to obtain better understanding of how a drug is transported 
through the BCECs and into the brain parenchyma, as well as how the drug will reach 
the pathological site. But why is it so difficult to achieve? The problems start within 
the blood circulation as therapeutics are usually designed to be administered i.v. This 
can trigger immune activation to the foreign object. Liposomes are a great example of 
this. To combat this immune activation, liposomes can be conjugated with 
polyethylene glycol (PEG) to increase stability and prolong circulation time but to 
researchers concern, multiple studies have reported unexpected immune responses 
even with PEG conjugation. It is important to note that immune reactions can happen 
whether the liposome is targeted or not (286). Another problem is off-target 
accumulation of therapeutics after systemic administration, which has been the 
biggest problem in passive drug delivery, causing toxicity and lower efficacy of the 
drug (123). Unfortunately, targeted therapy does not completely eliminate this 
problem as the drug can accumulate in organs that express the receptor for the ligand 
that has been utilized for the targeting. If we take the TfR1 as an example, it is true 
that the BCECs are the only endothelial cell within the body that expresses TfR, but 
multiple other cell types, such as erythrocytes and macrophages, do also express the 
receptor. This can cause the accumulation in liver, spleen, kidney heart and lungs 
(287). 
Even if the drug surpasses these obstacles and actually binds to the ligand on the 
BCEC, there is no guarantee that the drug will be transported into and across the 
BCEC. It seems to be of great importance how the ligand binds to a receptor 
(288,289). Lowering the affinity of TfR-targeted antibodies seems to increase the 
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uptake (288), but whether this factor is specific to TfR-targeted antibodies is 
unknown. After the ligand of the drug complex has bound to the receptor on the 
BCECs, the strength of the ligand-receptor complex, the avidity, can highly affect 
transport (290,291). Even if all of these aforementioned pitfalls are evaded, when 
utilizing carrier-mediated transcytosis and receptor mediated transcytosis, which are 
vesicular routes, the drug or nanoparticle must escape lysosomal degradation within 
the BCECs to provide a therapeutic effect (14). And at last, as if the road hasn’t been 
long enough, the drug needs to be transported out of the BCECs and to the 
pathological site.  
Non-targeted transport of otherwise promising drugs has not been prosperous in the 
past, thus it is time to take a step back and investigate the target molecules better, from 
its expressional pattern to how it interacts with and transport therapeutics.  
The industry has taken notice, and pharmaceutical companies have started to develop 
targeted drug delivery systems. Here some of the most promising candidates will 
briefly be discussed.   
Roche was the first to enter the clinical phase using a brain delivery system, or their 
so-called “Brain Shuttle”, delivering anti-Aβ mAb trough targeting the TfR1. Their 
preclinical research displayed an uptake of 2-3% of the ID where protein 
concentrations was 9 times higher in AD mice compared to wild type mice (292). The 
initial trial RO 7126209 is completed (293) where the second study has begun on 
participants with prodromal, mild or moderate AD (294). 
Denali Therapeutics was founded in 2015 with the main purpose of designing 
therapeutics for neurodegenerative diseases that were able to pass the BBB. At that 
time, they received the largest initial funding for a biotech company ever, 217 million 
dollars. They have designed a transport vehicle that consisted of Fc fragment that 
binds to TfR1, which proved efficient in lowering the levels of amyloid protein in 
mice and monkeys when delivering an antibody against β-secretase 1. Furthermore, 
in a mouse model of Hunter syndrome the transport vehicle delivered 20 times the 
amount the therapeutic enzyme compared to when the enzyme was injected alone 
(295–297). Denali has progressed to early clinical testing of their enzyme transport 
vehicle, DNL310, which delivers recombinant iduronate 2-sulfatase enzyme that is 
deficient in Hunter syndrome (298).  
It will be interesting to follow the progress of these delivery systems that up until now, 
have only utilized TfR1 as a target. However, it may not be the best target for all 
neurodegenerative diseases.  
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5.2. EPIGENETIC REGULATION OF BRAIN CAPILLARY 
ENDOTHELIAL CELLS TRANSPORTERS   
The focus of the current thesis was only on a small part of the drug delivery equation, 
which is how targets on the BCECs are expressed in healthy animals and during 
neuroinflammation, and whether expression can be altered using epigenetics. The 
latter has not been investigated before from a drug delivery point of view. Obviously, 
choosing the right target is not going to solve all problems with drug delivery, but 
understanding how a target molecule is expressed by the BCECs in response to a 
disease state, or being able to influence the expression is a step in the right direction.  
Alterations in the epigenome are related to cognitive decline, neuropsychiatric 
disorders and neurodegenerative diseases (299). The use of drugs that target the 
epigenetic mechanisms have therefore emerged as new therapeutic opportunities. The 
gene expression will be influenced by how tightly packed chromatin is on histones. 
Increased acetylation will disrupt the folding of nucleosome and increase the 
accessibility of transcriptional factors (196,197). This can be manipulated with 
medications capable of inhibiting enzymes that are important in the acetylation and 
deacetylation process. VPA inhibits histone deacetylase and the deacetylation process, 
which enhances gene transcription (199). HDAC inhibitors, such as VPA, do 
modulate the gene expression of multiple genes, which represents a promising 
approach when targeting multifactorial diseases such as cancer and AD. The 
possibility of modulating two or more targets that are involved in a disease could 
result in a synergic positive effect (299). HDACs have therefore emerged as potential 
therapeutic targets for neurodegenerative diseases. The use of HDAC inhibitors in 
preclinical treatment of Tg2576 model of AD was able to reverse cognitive deficits in 
mice by inducing the expression of genes related to synaptic transmission (300). 
HDAC inhibitors have, furthermore, been used for cancer therapy as they display a 
broad anti-tumor activity. However, they also increase the expression of ABC efflux 
transporters on the tumor cells, making them more resistant to multiple drugs (301–
303). The broad effect of HDAC inhibitors is therefore not always beneficial.  
In regards to the BBB, it has been demonstrated that HDAC inhibitors are able to 
upregulate protein expression, as inhibition of HDAC increases the expression of tight 
junction proteins and reduces the transendothelial permeability in Type 2 diabetes 
mice (304). This was also demonstrated in vitro in Manuscript I (194), where we were 
able to upregulate the iron exporter ferroportin significantly in primary rat BCECs.  
Looking at these findings, it was evident that this could be a promising prospect for 
delivering more therapeutics via certain receptor or transporter. As the maximum 
transport capacity of a drug complex is dependent on the surface availability of a 
receptor or transporter (92), it was interesting to see if it was possible to upregulate 
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the expression of prominent brain drug delivery targets, including TfR1, Glut1, and 
CD98hc, in vitro and in vivo. Only TfR1 displayed significantly higher mRNA 
expression in vitro after VPA treatment. In order to see how the expression of 
aforementioned targets was affected in the BCECs in vivo following VPA treatment, 
both male and female mice were treated with VPA. There was no increase in CD98hc 
mRNA expression in the capillary depleted samples. Interestingly, only male mice 
increased their mRNA expression of Glut1 following VPA treatment in the capillary 
depleted samples, whereas the females did not. This raises the question whether there 
are different expressional regulatory mechanisms for Glut1 in the brain of males and 
females. This is unquestionably interesting as reduction of Glut1 expression in the 
BCECs is thought to occur early in the disease course of AD and known to worsen 
AD pathology, where women are more often affected by AD than men (305,306). 
TfR1 protein expression was increased in vivo in the capillaries following VPA 
treatment, without any sign of upregulated TfR1 mRNA in the capillary depleted brain 
samples. Thus, the upregulation of TfR1 seems to be specific for the BCECs. A 
possible explanation for why VPA could be specific to BCECs is that the uptake of 
VPA across the BCECS is slower than the efflux transport of the drug, which prevents 
VPA from sustaining a therapeutic concentration within the brain parenchyma (98). 
On the contrary, VPA was able to upregulate Glut1 expression in male mice, which 
might suggest that the transcriptional regulation of Glut1 is highly adaptable and 
responds to transcriptional signals faster than TfR1.   
When looking at the increase in TfR1 protein in capillaries, we were unsure if the 
increased expression was due to an increase in the intracellular pool of TfR1, or if the 
receptors were available on the BCECs surface. Hence, we investigated the surface 
availability by measuring the transport of injected anti-TfR gold-conjugated Ri7 
antibody to the brain. The transport of the Ri7 antibody was similar between the 
control animals and the VPA treated animals, which suggests that the quantity of 
surface TfR1 remains unaltered despite of the overall increase in TfR1 within the 
BCECs. This indicates that the increased TfR1 protein content in capillaries is mainly 
due to a larger intracellular TfR1 pool. The exact mechanism of TfR1 trafficking in 
the BCECs remains unclear, however, the cells iron concentration impacts the 
concentration of TfR1 and consequently the uptake of transferrin-bound iron. When 
cellular iron concentrations are low, the iron-regulatory proteins bind to iron 
responsive elements on the 3´untranslated region on the TfR1 mRNA, protecting it 
from degradation. The protein will thereafter be transported to the cell membrane, 
ensuring sufficient TfR1 availability (307). On the contrary, when intracellular iron 
concentration is high, no binding will occur leaving the TfR1 mRNA exposed to 
degradation (307). In normal circumstances where iron concentration is in equilibrium 
with the cells requirement, TfR1 protein may not be transported to the cell membrane 
as there is no need for additional iron import. Hence, increased TfR1 expression 
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within the BCECs due to VPA treatment does not guarantee that the protein will be 
transported to the cell membrane.  
Of the nutritional transporters and receptors that were investigated for epigenetic 
regulation, those that were significantly affected at both mRNA and protein levels by 
VPA treatment were TfR1 and ferroportin. These are both implicated in iron 
regulation, where TfR1 regulates iron uptake and ferroportin iron export. Iron 
homeostasis is known to be out of balance in neurodegenerative diseases, where an 
increase in cerebral iron levels has been implicated in neurodegenerative diseases that 
present with protein aggregates, which then seem to co-localize with iron (308). 
Exactly how iron transport at the BBB is affected by VPA treatment in e.g. epilepsy 
patients is an interesting research question. However, as our results suggest an 
increase in these proteins can occur without it affecting the surface availability and 
thereby transport of iron. Thus, in future studies, it is important to increase the luminal 
surface availability and activity of the receptors for targeting purposes.  
 
5.3. HOW DOES INFLAMMATION INFLUENCE THE EXPRESSION 
OF DRUG DELIVERY TARGETS?  
In addition to investigating whether TfR1, Glut1, and CD98hc could be 
pharmacologically upregulated using HDAC inhibitors, this dissertation focused on 
investigating how neuroinflammation affected the expression of these targets. Most 
drug delivery studies investigate young and healthy animals, neglecting the fact that 
the population they would like to treat in the future are in fact older and affected by 
neurodegeneration. There has been an ongoing debate on the extent of BBB disruption 
in neurodegenerative diseases (309,310). It is generally believed that there is some 
form of BBB breakdown, even in the early phases of neurodegenerative diseases 
(311), but the severity of the breakdown and duration is more uncertain. However, it 
is becoming more apparent that the dynamic BBB is not universally leaky in 
neurodegenerative diseases. 
After establishing an inflammatory BBB model where only mixed glia cells were 
stimulated with LPS, it displays only minor breakdown of the BBB with 10-30% 
decrease in TEER, which is lower than other in vitro models where LPS affects the 
BCECs directly (159,312). The inflammatory response was simulated well in our 
model as the mixed glial culture secreted various cytokines, thereby mimicking the 
diverse response of neuroinflammation. The exact cytokines that are secreted during 
neuroinflammation is difficult to confirm, as it could be dependent on the duration of 
the neuroinflammatory state, type of neurodegenerative disease as well as age and sex 
of the patient, but TNF-α, IL-6 and IL-1β seem to play a vital role in neuro-
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inflammation (313–315). The heterogeneity of the neuroinflammation in 
neurodegenerative diseases is thought to be due to the origin of the inflammation 
itself. In MS, even though residential microglia and astrocytes also produce cytokines, 
the major producer of inflammatory cytokines within the brain are invading 
leukocytes, and the changes in the brain tissue that follow are usually more severe and 
acute compared to AD (313). In AD, where the main producer of inflammatory 
cytokines that drive neuroinflammation are microglia and astrocytes, it is more 
unclear whether this secretion is beneficial or detrimental, at least in the beginning of 
the disease (313). The secretion may be beneficial as a response to a given stimuli, 
but chronic overproduction of pro-inflammatory cytokines can enhance the 
degenerative process (313). The broad secretion of inflammatory cytokines in the in 
vitro BBB model did affect the BCECs, not only by slightly decreasing the integrity 
of the barrier, but also by increasing the expression of the adhesion molecules ICAM-
1 and VCAM by the BCECs. The expression of these adhesion molecules is crucial 
for leukocyte migration into the brain parenchyma in response to neuroinflammatory 
injury. The novel inflammatory model could therefore be beneficial for investigating 
paracellular transport of molecules during neuroinflammation, as well as leukocyte 
migration across the endothelium. 
The purpose of establishing a neuroinflammatory in vitro BBB model was also to 
enable the investigation of the BCECs target molecules TfR1, Glut1, and CD98hc and 
compare it to the expression in LPS treated mice. The rational for investigating the 
availability of these targets on the BCECs following neuroinflammation was to ensure 
that they remain feasible targets for drug delivery, as neuroinflammation is an 
inevitable part of neurodegenerative diseases. Reduction in Glut1 expression at the 
BBB in AD has been reported, thereby questioning its efficacy as a target (11,305). 
On the other hand, the expression of TfR1 seems to be stable in mouse models of AD 
and in patients compared to controls (309). No study has been carried out on the 
expressional alteration of CD98hc in neurodegenerative diseases. Both TfR1 and 
Glut1 expression seemed unaffected by the inflammatory stimuli in the barrier model 
but the expression of CD98hc was undetectable in the BBB model. It is important to 
keep in mind that the inflammatory stimuli provided in the BBB in vitro model is a 
short and acute form of inflammation, and can therefore only provide us with 
information on the short-term effect of neuroinflammation on the aforementioned 
targets.  
In order to see how persistent neuroinflammation, although not completely 
comparable to the long lasting neuroinflammation in neurodegenerative diseases, 
impacted the expressional pattern and distribution of TfR1, Glut1, and CD98hc in 
mice, they were treated with LPS daily for seven consecutive days. The hypothesis 
was that animals euthanized 24 hours after last injection would mainly be affected by 
systemic inflammation, whereas the animals that were euthanized seven days after 
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last injection would have cleared the systemic inflammation and be left with only 
neuroinflammation. This was not the case as the animals seemed to be equally as 
affected systemically one day and seven days post injection. The neuroinflammatory 
effect was visible both 24 hours and seven days post injection, as demonstrated by 
increased expression of CD11b, ICAM-1, and VCAM. 
The distribution and expression of TfR1, Glut1, and CD98hc was investigated in 
animals that were euthanized seven days post LPS injection. The expression of 
CD98hc was stable between control animals and LPS treated animals, however the 
expression did not seem to be enriched in the vasculature and was universally 
distributed over the brain parenchyma. When CD98hc was suggested as a potential 
target in BCECs, it was due to the fact that it was enriched compared to endothelial 
cells elsewhere in the body (95), but that may not be sufficient to categorize as a great 
target. Still, CD98hc has recently been identified as one of the most abundantly 
expressed transporter on the BCECs in humans, and that the level of expression is 
very similar between mouse and human brains. Furthermore, it was demonstrated that 
the high expression of CD98hc transcripts within the mouse brain was mainly in the 
brain microvessels (316). As this is in opposition to the thesis´s results, further 
investigations should be carried out to clarify this discrepancy.  
Glut1 is one of the most abundantly expressed proteins in the BCECs making it an 
interesting target on the BBB. Glut1 is furthermore expressed on both the luminal and 
abluminal membrane, which could enhance the continued transport of the targeted 
molecule (77,85,88–90). Even though Glut1 seems like an optimal target in healthy 
animals, it may not be ideal in neurodegenerative diseases, as its expression is 
downregulated in AD (11,90,305). There are multiple pathological aspects in AD that 
could contribute to the downregulation of Glut1, and neuroinflammation is only one 
of them. We found that Glut1 was highly expressed in the endothelium in vivo and no 
drastic changes in expression or localization was observed between control animals 
and the LPS treated animals. However, in order to detect small expressional 
alterations in any of the targets, a quantitative analysis such as ELISA should be 
performed.  
TfR1 has been extensively studied for targeted BBB delivery. It has furthermore been 
demonstrated that transport of TfR1-targeted mAbs was not impaired by AD 
pathology (135). We found that TfR1 was highly expressed in capillaries, and as 
expected there was also some staining of neurons they also express TfR1 
(12,317,318). Similarly to Glut1, no dramatic alteration in the expression was 
observed.  
Future studies could include protein quantification of these drug delivery targets, 
preferably in older animals, as they could respond quite differently to the 
inflammatory stimuli.  
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5.4. UPREGULATION OF OTHER SUITABLE TARGETS IN BRAIN 
CAPILLARY ENDOTHELIAL CELLS IN RESPONSE TO 
NEUROINFLAMMATION 
The aforementioned targets were identified as suitable targets due to their high or 
selective expression in the BCECs in healthy animals, but the expression of receptors 
and nutrient transporters feasible for targeting may be altered due to aging, 
inflammation, and neurodegenerative pathology. There may also be transporters or 
receptors on the BCECs that may not seem as suitable targets in a healthy subject, but 
may be strongly upregulated during neurodegeneration. Although many of the 
alterations that occur in BCECs in response to inflammation are detrimental, they 
should not be overlooked in the search for suitable targets for enhanced drug delivery. 
ICAM-1 and VCAM are great examples, as they are upregulated in BCECs following 
inflammation, VCAM even more so than ICAM-1 (319). This is demonstrated in our 
LPS experiment, where LPS treated animals did increase the expression of especially 
VCAM following inflammatory stimuli, and the expression was still increased seven 
days after the last injection. Utilizing this fact as a treatment possibility has been 
performed in Experimental autoimmune encephalomyelitis (EAE) model of MS, 
where blocking of VCAM delayed disease onset (171). The ultimate proof of the 
importance of VCAM and the validity of inhibiting the interaction between VCAM 
and immune cells takes place when using Natalizumab, that efficiently limits the 
immune cell transport across the BBB, thereby limiting the tissue damage (320). But 
how can this be translated into BBB targeting? Recently, an inflammatory mouse 
model of acute brain inflammation induced by TNF-α displayed a 10-fold greater 
uptake of injected antibodies when targeting VCAM compared to TfR1 and ICAM-1 
(321). Likewise, the uptake of anti-VCAM liposomes was 27-fold greater than that of 
anti-TfR1 liposomes and 8-fold greater than of anti-ICAM liposomes (321). This is 
just one example of how the alteration in protein expression due to pathology can be 
utilized, and further demonstrates how important it is to have an all-around 
understanding of the structural differences and functions of the healthy and inflamed 
BBB in order to deliver targeted therapeutics successfully to the inflamed brain.  
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CHAPTER 5. CONCLUSION AND 
FUTURE PERSPECTIVES 
In conclusion, the projects of the PhD thesis have provided new insight into the 
expression of novel drug delivery targets expressed by the BCECs. Although 
neuroinflammation is implicated in neurodegenerative diseases, little is known about 
the expressional alteration or translocation of receptors and nutrient transporters that 
have been assessed as optimal targets for drug delivery. The results presented in the 
current thesis demonstrate that TfR1 and Glut1 remain stable in their expression 
during acute neuroinflammation in vitro and prolonged neuroinflammation in vivo. A 
novel in vitro neuroinflammatory model that preserves the integrity of the barrier was 
established, which could prove valuable in future studies on drug delivery or cellular 
transport through the inflamed BBB. Future studies should investigate the distribution 
of these targets in the BBB in neurodegenerative disease models to comprehend 
whether the expression is affected. Furthermore, future studies should investigate the 
potential of dual targeting during neuroinflammation, utilizing e.g. VCAM and TfR1.  
In addition to valuable insight into the regulation of targets in response to 
neuroinflammation, the projects of this dissertation have, as the first ones, investigated 
the potential of epigenetically upregulating molecular targets of interest on the 
BCECs. Upregulation of both ferroportin and TfR1 mRNA and protein was 
demonstrated in the BCECs, but further research is needed in order to understand how 
to increase the luminal surface availability of these for targeting purposes. 
Together, these finding may serve as inspiration for investigating how pathology in 
various neurodegenerative diseases might affect receptors or nutrient transporters 
chosen for targeted drug delivery in the future, and maybe even for discoveries of new 
and feasible targets. It is my hope that more research will be carried out utilizing the 
expressional alterations that consequently follow the pathology of neurodegeneration, 
and that it will pave the way for new and innovative ways of treating these diseases. 
Furthermore, there will hopefully be more focus on epigenetic agents and their 
potential to enhance the expression of genes that may be in deficit in certain 
neurodegenerative diseases.  
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